Talk:Michael P. Snyder

Greetings
I am McGuire at Snyderlab (https://en.wikipedia.org/wiki/User:Snyderlab). Following Blablubbs' instructions, I have requested a change in my username 'Snyderlab' to be 'McGuire at Snyderlab'. I work for Stanford University, School of Medicine and I'm the registered editor for the page: https://en.wikipedia.org/wiki/Michael_P._Snyder, on the https://en.wikipedia.org/wiki/Wikipedia:WikiProject_Biography/Members page. I do not have any conflicts of interest, I do however know Michal P Snyder, so I am requesting the following edits as I am a connected contributor, please read notice here:. I am responsible for keeping the page factual and up-to-date. Please inform Blablubbs and/or myself if you have any questions, thank you. Reason for requested edits: Without my edits, the Michael P Snyder page is not factual, as research and companies have been merged, formed and co-founded, and important new discoveries related to the COVID-19 virus are not viewable and transparent on this page. The significant advances in healthcare now absent from this page have been communicated to me recently by Nobel Prize Winners, concerned about the global impacts if this page is not kept up-to-date. I request that anyone assisting me in making these updates, do so following the regulations of Wikipedia. Regards, McGuire at Snyderlab | I am a connected contributor, |  McGuire at Stanford Snyderlab (talk) 05:55, 6 February 2021 (UTC)

Regarding Requested Edits: McGuire at Stanford Snyderlab (talk) 05:55, 6 February 2021 (UTC) My edits are very small and consist of changing a few words by ensuring that they are referenced properly to show the source of research and healthcare organizations and companies. my only edits exist in the 'Entrepreneurship' section. However, after I made my edits, most of Michael P. Snyder's page was deleted thus now shows inaccurate information. Pasted below is the page as it was over the past year, including my small edits in the Entrepreneurship section:

Here is the version of the page I would like to request:

Michael Snyder (born 1955) is an American genomicist, systems biologist, and entrepreneur. He is the Stanford B. Ascherman Professor and Chair of Genetics and Director of Genomics and Personalized Medicine at Stanford University School of Medicine.

Early life and education
Snyder was born 1955 and grew up outside of Pottstown, Pennsylvania. His father, Kermit Snyder, was an accountant and his mother, Phyllis Snyder, was an elementary school teacher. Snyder attended Owen J Roberts High school in Pottstown, Pennsylvania. He won a Bausch & Lomb science award and attended the University of Rochester, NY where he received a B.A. in Chemistry and Biology. Upon graduation Snyder worked as a research assistant with Karl Drlica at the University of Rochester. Snyder received a PhD in biology from the California Institute of Technology, where he trained in the laboratory of Dr. Norman Davidson. Recombinant DNA was relatively new at the time and by using this technology to clone a set of gene encoding Drosophila cuticle proteins, Snyder discovered that related genes are often co-associated with one another in the genome (1,2). He also discovered one of the first pseudogenes in eukaryotes (2) and made the fundamental discovery that transposons often land in open promoter regions of eukaryotic genes when he discovered a new transposon, HMS Beagle, located in the promoter of an inactivated Drosophila cuticle gene (3).

Career
Snyder completed his postdoctoral training at Stanford School of Medicine in the laboratory of Dr. Ronald Davis. There he was involved in several projects including establishment of successful cloning of genes using antibodies (lambagt11;) (4). The expression libraries he created were used widely by thousands of laboratories worldwide.

Snyder moved to Yale as an Assistant Professor in 1986 in the Department of Biology. His laboratory worked on chromosome segregation and cell polarity for which he discovered a number of important genes involved in these processes (5,6). His laboratory proposed the first models by which eucaryotes select sites of cell growth (7,8).

He was promoted to Associate Professor with tenure in 1994, and when the Biology Department split in the Molecular, Cellular and Developmental Biology (MCDB) and Ecology and Evolutionary Biology, he became chair of the new MCDB department. During his six years as chair the Department doubled in size and tripled in research funding. He was also the Director for the Center for Genomics and Proteomics at Yale University.

In 2009 Snyder moved to Stanford University to Chair the Genetics Department and to direct the Center for Genomics and Personalized Medicine. Since 2010 the U.S. News & World Report has ranked Stanford University first or tied for first in Genetics, Genomics and Bioinformatics.

Snyder was elected and has served as President of US Human Proteome Organization (2006–2008) and Human Proteome Organization (2017-2018). He has served on numerous scientific advisory committees (e.g. EMBL Scientific Advisory Committee) and is on the Genetics Society Board of Directors (2006–2009). He has organized many scientific meetings.

Snyder has been Principal Investigator of Center of Excellence in the Genome Sciences (CEGS) (2001–2011), NIH Training Grants in Genomics and Proteomics (first at Yale, now at Stanford) (2004–present), and is coDirector of the CIRM Center for Stem Cell Genomics and Director or the Center for Genome of Gene Regulation. He has been a Principal Investigator in the ENCODE project since its inception in 2003.

Research accomplishments
In addition to contributions to the field of cell biology, Snyder’s laboratory has invented a number of novel systems-wide and genomics technologies, and his laboratory has used these to make fundamental biological discoveries.

Systems analyses and Omics Technologies
At a time when most laboratories were studying one or a limited number of genes at a time, Snyder’s laboratory set up the first large scale systems project to study all yeast genes and proteins simultaneously using a transposon tagging strategy to analyze gene expression, protein localization and gene disruption (9,10). This was the first large-scale systems analysis of genes and proteins in any organism and launched the field of functional genomics. The libraries and approaches were widely utilized by many laboratories around the world and launched the concept of open sharing and reagents, prior to publication. With Dr. Patrick Brown’s laboratory, the Snyder laboratory invented ChIP-chip (11) (which they later morphed into ChIP-seq (12) to carry out the first genome wide mapping of transcription factor binding sites. Initially established for yeast(11), they later applied the methods to humans (13). This method was foundational for multiple multicenter consortia projects including the Encyclopedia of DNA Elements project (ENCODE; (14)). Their laboratory constructed the first human chromosome array (15) and later the first whole genome array (16) to map TF binding sites and novel transcribed regions of the genome. They later invented RNA-seq to better map transcriptomes, both protein coding and noncoding (17,18). Today, this technique is widely employed in the molecular biology field. With the advent of high throughput DNA sequencing technologies, the Snyder laboratory was the first to sequence an organism using such technology, at a time when most groups thought the technology was too error-prone to be useful. They sequenced Acinetobacter Baummanii, a human pathogen with low error rates (19). They invented paired end sequencing using new high throughput sequencing technologies (20) and used this to demonstrate that there was ten times as much structural variation (SV) in the human genome a previously realized and that most SV deletions and insertions were due to nonhomologous recombination, a surprising finding at the time, since most SVs were proposed to be due to homologous recombination events. Beyond the genome, the Snyder lab was also the first to set up protein and proteome microarrays for the large-scale characterization of protein function and antibody reactivity (21,22). They demonstrated many novel biological activities of protein kinases and other yeast proteins and showed they can be useful for autoantibody profiling (23).

Biological discoveries
Through their genomics efforts the Snyder laboratory has found that there are many more TF binding sites than were previously appreciated (13), with more potential regulatory sequences than RNA coding segments in the human genome (10% versus 3%)(24). In addition to TF binding sites, the Snyder lab discovered that twice as much of the human genome is transcribed into the mature RNA (16), revealing the widespread occurrence of lincRNAs. These lincRNAs have since been shown to have a diverse array of interesting cellular functions. Much attention has been paid to understanding the differences individuals and species. The Snyder laboratory was the first to show that transcription factor binding sites vary greatly among people (25) and closely related species, demonstrating that much of the diversity among individuals and closely related species resides at the level of gene regulation (27,28), rather than the genes themselves. Much of this variation resides in distal regulatory elements called enhancers.

Omics profiling and data driven medicine
Using the same in-depth omics approaches he applied to yeast, upon his move to Stanford in 2009, Snyder began to apply systems-wide analysis to human health (29). The Snyder laboratory carried out the first deep longitudinal profiling of one person using multi-'omics technologies (genomics, transcriptomics, proteomics, metabolomics, etc.). This deep profiling used genomics for the first time to predict disease risk and follow disease onset at a level not previously achieved (29). This work was recognized as a landmark paper in the journal Cell's 40th anniversary celebration in 2012. This approach of collecting longitudinal deep data on humans is now being applied by many groups worldwide. The Snyder lab has recently demonstrated that self-tracking using wearable biosensor can be used for monitoring health and illness (30). Together these studies demonstrate the power of using longitudinal tracking and big data to manage human health.

Entrepreneur
Dr. Snyder is the founder of Qbio and co-founder of several Biotechnology companies. These include: Personalis, SensOmics, January, Filtricine, Mirvie, Protos, Exelixis, Protometrix (purchased by Life Technologies, now part of Thermo Fisher), Affomix (purchased by Illumina and SensOmics.  He also sits on the board of numerous other biotechnology companies.

Dr Snyder is the author of the book: 'Genomics and Personalized Medicine: What Everyone Needs to Know'.

Awards
Snyder has received the following awards:


 * Pew Scholars (1987)
 * Lewis B Cullman named chair (1996)
 * Connecticut Medal of Science (2007)
 * Stanford B. Ascherman named chair (2010)
 * Member of the American Academy of Sciences (elected 2015)
 * George W. Beadle Award, Genetics Society of America (2019)

He has been listed in the "Most Cited Scientists since 2014" and has given many distinguished and named lectureships. Since 2009 these include:


 * Univ of Pennsylvania, Bernard Cohen Lecture (2009)
 * EMBL Dintinguished Lecturer (2011)
 * Distinguished Green Lecture Series in Systems Biology at UT Dallas (2012)
 * Honorary Lecture at the Genetica Retraite in Rolduc, Maastricht (2013)
 * Valdosa College Connell Lectureship (2013)
 * Walbash College Special Lectureship (2013)
 * General Electric Lectureship McGill Univ. (2014)
 * Greenberg Lectureship, Univ. of Michigan (2014)
 * Burdette Lecture, Univ. Texas, Austin (2015)
 * Murdock Lecture in Stockholm (2015)
 * Gerald Aubach Lecture ASBMP (2016)
 * Distinguished Lectureship, Cedars-Sinai (2016)
 * UC Davis/UC Dublin Kinsella lectureship/Award (2016)
 * Wright Lecture in Geneva (2016)
 * Gibbs Lecture (2017)

Publications and book
Snyder has authored over 500 published manuscripts.

He has authored a book for a general audience: "Genomics and Personalized Medicine: What Everyone Needs to Know". Oxford University Press. 2016. It describes the utility of genome sequencing, other omics technologies and big data in medicine and prospects for the future.

Given now draftified...
...the declared paid editor McGuire instructed to edit the draft directly. David notMD (talk) 13:47, 7 February 2021 (UTC)


 * Thank you to the group of editors who are editing Michael P. Snyder's page today.

I'm making my suggested edits to the Michael P. Snyder page here before attempting to make any edits as I am a connected contributor. I will be adding additional requests over the next week for your review & valued critique.

Enormous thanks to the Wikipedia authors/editors of https://en.wikipedia.org/wiki/Robert_S._Langer Robert S. Langer's page as they have helped me tremendously in accurately formatting this similarily notable scientist. We have added considerable verified sources similar to Robert S. Langer's page, and they are helping me to continue improving on the quality of this page.

Please add any additional or better sources/references/improvements to this page!

We are not done as we are attempting to get the entire list of companies Michael P. Snyder has founded (which is extremely long it appears) and have it look like Robert S. Langer's list of companies. That is our next step.

Regards,

McGuire at Stanford Snyderlab Dec 16, 2021.

With that said, I am hopeful that editors who read this can add additional

1. I'm looking at the other Geneticists (from Category:American geneticists) (BTW: not many are still alive) in the group which Michael P. Snyder is a part of, and their similar references to peer-reviewed journals were kept visible, whereas Michael P. Snyder's long list of references were recently deleted - should we put them back? Also, I'm seeing that all the companies they founded and books they wrote are listed on their page, should we put these back on Michael P. Snyder's page or hide the facts that Michel P. Snyder owns these companies from public view? Listed below in 2. are "people not affiliated with Snyder or Stanford who have written about his role in starting these companies" as requested by David notMD. I am looking for additional sources, though these companies are legally documented by the United States Government as well and I don't see this reference required on other Category:American geneticists pages who have founded companies.

2. Below are several organizations and "people not affiliated with Snyder or Stanford who have written about his role in starting these companies" - which are not peer-reviewed journals and may help the current group who are rewriting the Michael P. Snyder article, as omitting the truth about the companies he has founded (basically omitting his entrepreneurship) is omitting the facts, and we are all here to help Wikipedia reveal facts, not hide them: https://www.crunchbase.com/person/michael-snyder-2 https://www.r42group.com/michaelsnyder https://education.23andme.com/webinars/big-data-and-human-health/ https://www.geekwire.com/2017/wearable-sensors-knew-researcher-getting-sick/ https://www.olink.com/sf-oct-2017/ https://www.prweb.com/releases/labroots_highlights_harvard_university_geneticist_dr_george_m_church_and_stanford_university_genomicist_dr_michael_snyder_in_genetics_genomics_2019_virtual_event/prweb16235398.htm

Thank you, McGuire at Stanford Snyderlab (talk) 14:20, 7 February 2021 (UTC)
 * Those sources don't seem to be reliable. We certainly can't use passing mentions, profiles and press releases. Theroadislong (talk) 14:25, 7 February 2021 (UTC)

Although I pointed you to articles about Stanford academics as examples, flaws in those articles do not justify the same shortfalls in the draft for Snyder. My main intent was to show you examples that had references about the people who are subjects of the articles rather than deeply detailed descriptions of their research. David notMD (talk) 02:49, 8 February 2021 (UTC)

coi (you requested my comments)
To put it directly, as a member of his group, you should not have written this article. Almost nobody has been successful in doing this. The main fault with the article at present is the use of buzzwords, and repetition. We do not copy all the positions into the infobox, only the highlight. We do not make the presumption that the growth of the department is due primarily to him as chair. We do not try to refer to as many as his articles as possible. We downplay his commercial activities unless there is evidence that they are sufficient to be notable in their own right. They might be--it will be necessary to check if they have notetworthy marketed product. We do not consider a scientist who started a few companies to exploit his work to be an entrepreneur (for one thing we would need evidence it''s not just his ideas, but that he developed the company-that's what entrepreneur means).

An encyclopedia does not make a claim for " first" without at least one and better two extremely reliable third person sources--certainly not brief CVs he has written himself for conferences, or his own papers. . All scientists receive grants or they could not do their work: they are not awards in the usual sense and there is no need to mention them. All scientists join  professional organizations--we include them if they are president, not just member of the board. We do not use popular news sources to describe his work. to them in the text. This is one of the very few attempts at a scientist bio I have seen in WP that has the promotional excess of trying to include two extensive lists of major articles.

We usually do not give h factor  within the article---see our article on it to understand why it's considered ambiguous and unreliable. We do include a list of his 5 most cited articles, and only those.(And his importance is shown better by the actual very high values for his most cited articles) An encyclopedia article is not a CV. We don't try to get as many as possible in by including references

In his case, there is no shortage of major awards. We highlight them at the beginning of the article, so people know right away he's significant. For some reason you left out the most important, one that everybody will immediately recognize:: Member of the United States-National Academy of Science-tho it is in the infobox.

What I give is my opinion, there are no formal rules for article content, just a consensus about what is not admissable, The excellent reviers who have already examined the article would probably word it differently, but the general patter nI give is consistent. Erratic departures from it indicate coi, often from the person themselves.

''You would do well to explain furthe the exact nature of your conflictof interest, but unless it is a paid COI, details are no trequired. If it is a paid COI, they are required. Please respnd here and let me know on my talk page.'' DGG ( talk ) 05:43, 1 June 2022 (UTC)


 * You have said you work for the Stanford School of Medicine, but have no conflict of interest. If your job involves writing publicity for the school or the faculty of the school, according to our rules at WP:PAID, you do have a direct financial conflict of interest, and must specify it.  DGG ( talk ) 22:44, 23 June 2022 (UTC)